Drug Trial Radar · NCT02492711
Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 17, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
624
Actual
Start
Aug 24, 2015
Primary completion
Aug 11, 2021
Study completion Jun 14, 2022
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Jul 9, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether patients with metastatic breast cancer treated with margetuximab plus chemotherapy have longer progression free survival (PFS) and overall survival (OS) than patients treated with trastuzumab plus chemotherapy. A non-randomized sub-study cohort of approximately 88 patients will be enrolled to evaluate the safety of a reduced margetuximab infusion rate in patients receiving margetuximab either as monotherapy or in combination with chemotherapy.
Conditions
- HER-2 Positive Breast Cancer
- Metastatic Neoplasm
Interventions
MargetuximabBiological
15 mg/kg via IV (intravenous) infusion on day 1 of each 21 day cycle,
TrastuzumabBiological
8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion on day 1 of each 21 day cycle
Physician's choice of chemotherapy.Drug
Capecitabine (Xeloda®):1000 mg/m2 BID for 14 days in a 21-day cycle, or Eribulin (Halaven®): 1.4 mg/m2 on days 1 and 8 of a 21-day cycle, or Gemcitabine (Gemzar®): 1000 mg/m2 on days 1 and 8 of a 21-day cycle, or Vinorelbine (Navelbine®): 25-30 mg/m2 on days 1 and 8 of a 21-day cycle
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS) as Determined by Independent Radiological Review.Time frame: Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, average 5 months.
- Overall Survival (OS) Defined as the Number of Days From Randomization to the Date of Death (From Any Cause).Time frame: Throughout the study, average 21 months
- Number of Patients With Grade 3 or Higher Infusion Related ReactionsTime frame: 22 days
Locations
167 sites in 18 countries. Site status is shown where the registry gives one.
Ironwood Cancer & Research Center
Chandler, Arizona
Banner MD Anderson Cancer Center
Gilbert, Arizona
Western Regional Medical Center, Inc.
Goodyear, Arizona
East Valley Hematology And Oncology
Burbank, California
UCLA Hematology Oncology Santa Monica
Los Angeles, California
UC Davis Comprehensive Cancer Center
Sacramento, California
Sharp Memorial Hospital
San Diego, California
University of California, San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California
Kaiser Permenente Medical Center
Vallejo, California
Poudre Valley Health Care, Inc.
Fort Collins, Colorado
MedStar Washington Hospital Center
Washington D.C., District of Columbia
Florida Cancer Specialists
Fort Myers, Florida
Memorial Cancer Institute at Memorial Regional Hospital
Hollywood, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
Florida Cancer Specialists
New Port Richey, Florida
Orlndo Health Cancer Center
Orlando, Florida
Hem-Onc Associates
Port Saint Lucie, Florida
Palm Beach Cancer Center
West Palm Beach, Florida
Piedmont Cancer Institute, P.C.
Atlanta, Georgia
Northwest Georgia Oncology Centers, PC
Marietta, Georgia
CTCA - Southeastern Regional Medical Center
Newnan, Georgia
Kaiser Permanente Hawaii Moanalua Medical Center
Honolulu, Hawaii
Northwestern University Feinberg School of Medicine
Chicago, Illinois
Rush University Medical Center
Chicago, Illinois
Carle Cancer Center
Urbana, Illinois
CTCA - Midwestern Regional Medical Center
Zion, Illinois
Indiana University Health Goshen Center for Cancer Care
Goshen, Indiana
ARH Cancer Clinic
Hazard, Kentucky
St. Joseph's Hospital
Lexington, Kentucky
Touro Infirmary Hospital
New Orleans, Louisiana
New England Cancer Specialists
Scarborough, Maine
Mercy Medical Center
Baltimore, Maryland
Tufts-NEMC Cancer Center
Boston, Massachusetts
Forrest General Hospital
Hattiesburg, Mississippi
Saint Luke's Cancer Specialists
Kansas City, Missouri
Mercy Hospital Saint Louis
St Louis, Missouri
Dartmouth-Hitchcock - Norris C
Lebanon, New Hampshire
New Jersey Hematology Oncology Associates
Brick, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey
Saint Barnabas Medical Center - The Cancer Center
Livingston, New Jersey
Showing 40 of 167 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.